R&D channel feed – Endpoints News

R&D channel feed

Pfizer was warned of Lyme study problems months ago, trial research startup's CEO tells employees

3 years ago

Celldex fleshes out case for Xolair challenger in chronic hives

3 years ago

Merck’s Keytruda fails more prostate and lung cancer PhIII trials

3 years ago

Theravance cuts 17% of staff, JAK inhibitor program

3 years ago

Decades after breakthrough, scientists still puzzling over mRNA delivery

3 years ago

Suffering CNS player flips another losing hand in a last PhII gamble and calls for the axe

3 years ago

AstraZeneca expands Canada R&D work, to add 500 jobs

3 years ago

State attorneys general sue FDA over abortion pill access restrictions

3 years ago

Axsome says FDA wants more data for Alzheimer’s agitation label expansion, but readout to come sooner

3 years ago

Ahead of FDA decision, Blueprint puts out full data for expanded Ayvakit label

3 years ago

Kura Oncology drops multiple clinical programs for J&J-discovered tipifarnib

3 years ago

Galapagos goes 0-for-3 on inflammation program as it cuts an early-stage candidate

3 years ago

Novartis retreat from NASH takes down $80M alliance with Pliant Therapeutics

3 years ago

Nektar’s latest PhII flop threatens to unravel $400M-plus deal with Eli Lilly

3 years ago

Bristol Myers expands footprint in India with drug development and IT center

3 years ago

Moderna predicts $5B in 2023 Covid vaccine sales, reports net income loss and cost increases

3 years ago

FDA approves Sanofi's factor VIII hemophilia A drug

3 years ago

Pfizer cuts CRO unicorn from Lyme vaccine trial in dispute over conduct

3 years ago

Sickle cell R&D hit by three culls in one day at Novartis/Intellia, Sangamo and Graphite Bio

3 years ago

Following clinical hold lift, Astellas posts early Pompe gene therapy data

3 years ago

Graphite Bio gives up on lead sickle cell program, halves staff in wake of safety scare

3 years ago

Cerevel blames Covid for delayed neuroscience studies, says president is leaving

3 years ago

Another BioCryst Factor D inhibitor hits clinical delay two months after first one discontinued

3 years ago

BioNTech touts differences with Moderna in race for cancer vaccines

3 years ago

First page Previous page 95 96 979899 100 101 Next page Last page